Patient ‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma

American Journal of Hematology, EarlyView.

Source: American Journal of Hematology - June 20, 2018 Category: Hematology Authors: XavierLeleu , TamasMasszi , Nizar J.Bahlis , LuisaViterbo , BartrumBaker , PeterGimsing , VladimirMaisnar , OlgaSamoilova , LauraRosi ñol , ChristianLanger , KevinSong , TohruIzumi , CharlesCleeland , DeborahBerg , Source Type: research